Conformis Inc.

1.35-0.0100-0.74%Vol 9.93M1Y Perf 75.83%
Jul 23rd, 2021 16:00 DELAYED
BID1.34 ASK1.35
Open1.41 Previous Close1.36
Pre-Market- After-Market1.35
 - -  - -%
Target Price
2.50 
Analyst Rating
Moderate Buy 2.50
Potential %
85.19 
Finscreener Ranking
★★     45.91
Insiders Trans % 3/6/12 mo.
-75/-80/-89 
Value Ranking
★★+     49.15
Insiders Value % 3/6/12 mo.
-73/-76/-88 
Growth Ranking
★+     41.90
Insiders Shares Cnt. % 3/6/12 mo.
-76/-78/-90 
Income Ranking
 —    -
Market Cap246.34M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
82.39 
Earnings Date
4th Aug 2021

Today's Price Range

1.291.51

52W Range

0.60151.51

5 Year PE Ratio Range

-4.80-2.20

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
19.47%
1 Month
16.38%
3 Months
43.14%
6 Months
-3.57%
1 Year
75.83%
3 Years
33.66%
5 Years
-80.26%
10 Years
-

TickerPriceChg.Chg.%
CFMS1.35-0.0100-0.74
AAPL148.561.76001.20
GOOG2 756.3289.75003.37
MSFT289.673.53001.23
XOM57.04-0.0700-0.12
WFC44.59-0.4400-0.98
JNJ171.791.81001.06
FB369.7918.60005.30
GE12.710.01000.08
JPM150.64-0.2900-0.19
Financial StrengthValueIndustryS&P 500US Markets
3.80
4.30
0.25
0.35
-10.00
Leverage Ratio 2.20
ProfitabilityValueIndustryS&P 500US Markets
49.40
-36.30
-29.70
-52.10
-53.95
RevenueValueIndustryS&P 500US Markets
46.65M
0.26
-9.17
-3.01
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.08-0.09-12.50
Q04 2020-0.11-0.0827.27
Q03 2020-0.12-0.0925.00
Q02 2020-0.13-0.0376.92
Q01 2020-0.09-0.14-55.56
Q04 2019-0.10-0.0820.00
Q03 2019-0.11-0.13-18.18
Q02 2019-0.11-0.110.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR0.08260.00Positive
9/2021 QR-0.06-20.00Negative
12/2021 FY-0.1810.00Positive
12/2022 FY-0.24-41.18Negative
Next Report Date4th Aug 2021
Estimated EPS Next Report0.08
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume9.93M
Shares Outstanding182.48M
Trades Count21.98K
Dollar Volume6.11M
Avg. Volume4.20M
Avg. Weekly Volume6.40M
Avg. Monthly Volume3.03M
Avg. Quarterly Volume2.99M

Conformis Inc. (NASDAQ: CFMS) stock closed at 1.35 per share at the end of the most recent trading day (a -0.74% change compared to the prior day closing price) with a volume of 9.97M shares and market capitalization of 246.34M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 271 people. Conformis Inc. CEO is Mark A. Augusti.

The one-year performance of Conformis Inc. stock is 75.83%, while year-to-date (YTD) performance is 104.55%. CFMS stock has a five-year performance of -80.26%. Its 52-week range is between 0.6015 and 1.51, which gives CFMS stock a 52-week price range ratio of 82.39%

Conformis Inc. currently has a PE ratio of -3.80, a price-to-book (PB) ratio of 2.36, a price-to-sale (PS) ratio of 4.58, a price to cashflow ratio of 27.70, a PEG ratio of 2.32, a ROA of -24.76%, a ROC of -32.62% and a ROE of -54.28%. The company’s profit margin is -53.95%, its EBITDA margin is -29.70%, and its revenue ttm is $46.65 Million , which makes it $0.26 revenue per share.

Of the last four earnings reports from Conformis Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.08 for the next earnings report. Conformis Inc.’s next earnings report date is 04th Aug 2021.

The consensus rating of Wall Street analysts for Conformis Inc. is Moderate Buy (2.5), with a target price of $2.5, which is +85.19% compared to the current price. The earnings rating for Conformis Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Conformis Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Conformis Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 12.49, ATR14 : 0.10, CCI20 : 224.45, Chaikin Money Flow : 0.13, MACD : 0.06, Money Flow Index : 88.77, ROC : 27.36, RSI : 72.59, STOCH (14,3) : 69.20, STOCH RSI : 0.94, UO : 55.10, Williams %R : -30.80), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Conformis Inc. in the last 12-months were: J. Brent Alldredge (Sold 40 571 shares of value $31 801 ), Kenneth P. Fallon (Buy at a value of $18 494), Mark A. Augusti (Sold 319 689 shares of value $228 775 ), Robert S. Howe (Sold 19 101 shares of value $19 342 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
2 (50.00 %)
1 (33.33 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (25.00 %)
1 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (25.00 %)
1 (25.00 %)
1 (33.33 %)
Summary RatingModerate Buy
2.50
Moderate Buy
2.50
Hold
3.00

Conformis Inc.

Conformis Inc is a US-based medical technology company. It uses iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped to fit each patient's anatomy. The company's iFit technology platform comprises three key elements which are iFit design, iFit printing, and iFit just-in-time delivery. It offers various partial and total knee replacement implants which include iTotal CR, iTotal PS, iDuo, and iUni. The company operates in the segment of knee replacement market. Its total revenue generated from the sale of its products to hospitals and other medical facilities. The majority of the company's revenue comes from the United States.

CEO: Mark A. Augusti

Telephone: +1 781 345-9001

Address: 600 Technology Park Drive, Billerica 01821, MA, US

Number of employees: 271

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

63%38%

Bearish Bullish

54%46%

Bearish Bullish

50%50%

News

Stocktwits